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Abstract
Malignant pleural mesothelioma is a rare tumour, but its incidence is increasing. Imaging is invariably involved in its
diagnosis, staging, and follow-up. Although there are some characteristic radiological signs, none are pathognomonic.
Computed tomography (CT) and magnetic resonance (MR) have similar local staging accuracies, but have distinct
limitations; MR has marginal superiority in specific areas and should probably be offered to surgical candidates.
The capabilities of multidector CT await evaluation. The role of positron emission tomography (PET), and PET–CT
is undefined, but will likely have a major contribution. The challenges in imaging are matched by controversies in
staging and treatment, which require future close multidisciplinary and multicentre collaboration.
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Introduction
Primary malignant pleural tumours include diffuse malig-
nant pleural mesothelioma (MPM), localised fibrous
tumour, and pleural sarcoma, of which MPM is by far the
commonest (approximately 90%), and is the focus of this
article. Although a rare tumour, accounting for less than
1% of all thoracic neoplasms, diffuse MPM is assuming
increasing importance because of its rising incidence. In
Western Europe the incidence of MPM is expected to
continue rising for the next 2 decades.
MPM is a locally aggressive tumour that has histori-
cally been associated with refractoriness to most standard
forms of therapy and a dismal prognosis. However, in
more recent years there have been reports of improving
chemotherapy regimes, and some indication that multi-
modality therapy may offer some promise in selected
patients.
Imaging is crucial in the diagnosis of MPM, and it also
plays an important role in staging and follow-up.
Epidemiology and pathology
In Western Europe, the incidence of MPM is estimated to
be 2–15 per million, with 5000 deaths in 1998. In the UK,
there are approximately 1600 deaths/year. In the USA, the
incidence is approximately 7–13 per million white males,
with approximately 2300 deaths at the millennium [1].
The incidence and mortality rates have been consis-
tently rising, at about 5–10% per year, and is expected to
continue rising to peak in Western Europe in the period
2010–20, with an estimated 9000 deaths in 2018 [2]. The
incidences reflect population exposures to asbestos, with
a 20–40 year time lag. The peak incidence in USA
may have been reached because maximum exposures to
asbestos were in 1930–60, while in the UK this was in the
1970s. Incidences may continue to rise beyond the next
2 decades in developing countries in which appropriate
regulations have been, or are, less stringent.
The median age of disease is 60 years, and is more
common in men (two to six-fold), largely because of the
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occupational association discussed below. Women, how-
ever, may be involved by ‘collateral’ exposure through
their spouses, or environmental exposure. Spontaneous
occurrences are comparatively rare in both men and
women, and extremely rare in children.
Development of the tumour is essentially causally
associated with occupational exposure to asbestos: a
mineral fibre with heat and fire resistant properties. The
risk of MPM is a function of the dose of asbestos
exposure, and time to first exposure to the power of 3–4.
The most tumourigenic asbestos fibre is thought to
be crocidolite, with other subtypes including amosite
and chrysotile (‘blue’, ‘brown’, and ‘white’ asbestos,
respectively). The microscopic presence of ‘asbestos
(ferruginous) bodies’ is evidence of previous exposure
to asbestos. Other suggested aetiological factors include
exposure to other mineral fibres (e.g. zeolite or erion-
ite), chronic inflammation and scarring (e.g. TB and
empyemas), irradiation and intrapleural thorium dioxide,
genetic factors, and the viral oncogene Simian virus
SV40 (a contaminant in a number of human vaccines).
Mesotheliomas are tumours that arise from the serosal
lining of body cavities. The precise patho-physiological
origin of the tumour is not known. In the thorax, MPM
is thought initially to involve the parietal pleura, forming
grey–white pleural plaques and nodules ranging from 0.5
to 3 cm in thickness, and to subsequently involve the
visceral pleura, frequently fusing the two surfaces. The
tumour typically spreads locally along pleural surfaces,
including the interlobar fissures, in a confluent sheet-like,
lobulated or nodular form, eventually creating a pleural
‘rind’ and encasing and compressing the underlying
lung. The tumour is usually diffuse rather than focal.
Pleural effusions, sometimes large, may be a dominant
feature. The tumour is typically locally invasive, with a
tendency to involve the diaphragm, soft tissues and ribs
of the chest wall, pericardium and heart. The tumour
more commonly affects the inferior hemithorax (probably
because of gravitational effects), and the right side (60%,
probably because of the greater pleural surface on this
side). Bilateral disease is rare (<5%).
Contiguous spread to loco-regional lymph nodes
has hitherto been considered comparatively uncommon,
but recent studies have suggested involvement in up
to 50% of cases [3]. Lymphangitic spread may also
occur. Nodal metastases are present in 40–45% of
cases, with abdominal nodal metastases in 8% [4]. Simi-
larly, haematogenous spread, also previously considered
uncommon, is prevalent at post-mortem (50–67%) and is
being increasingly recognized as a mode of dissemination
at the time of staging and follow-up [5]. Metastases may
occur to the contralateral lung (20–80% at autopsy),
abdominal contents, bones, and brain. Liver metastases
are rare and may calcify. The diaphragm is frequently
invaded, and transdiaphragmatic spread to involve the
peritoneal cavity has been reported in one-third of cases at
post-mortem.
Of note, asbestos exposure is also associated with
benign pleural conditions, including benign pleural
plaques (hyalinized collagen fibres), diffuse pleural
fibrosis/thickening, and pleural effusions of benign
asbestos pleurisy. There is no evidence that benign pleural
plaques are premalignant or precursors to MPM [4].
Asbestos-related mesothelioma may also involve the
peritoneal linings, but is less common.
Pathological variants include epithelial (‘carcino-
matoid’, 55–65%), sarcomatoid (10–15%), or mixed
(‘biphasic’, 20–35%) subtypes. Pleural effusions are
more common in epithelial variants, while sarcomatoid
subtypes carry a worse prognosis.
Differential diagnosis
Differential considerations on gross morphology include
an organising pleural effusion, chronic infection (e.g.
tuberculosis), connective-tissue disease, and talcosis. The
diagnosis is made more challenging because asbestos
exposure, as indicated above, is associated with a range of
benign pleural diseases, which are in fact more common
than MPM.
MPM can also be a challenging pathological diagnosis,
for example: epithelial mesothelioma vs. metastatic
adenocarcinoma (e.g. from lung, breast, stomach, kidney,
ovary or prostate), sarcomatoid mesothelioma vs. sar-
coma (e.g. fibrosarcoma), and mixed/biphasic mesothe-
lioma vs. sarcomatoid carcinoma or synovial sarcoma.
Differentiation of MPM from benign disease can also
be challenging, for example: well-differentiated epithelial
mesothelioma vs. reactive mesothelial proliferation,
sarcomatoid or desmoplastic mesothelioma vs. benign
reactive pleural fibrosis, and benign vs. malignant
mesothelial proliferation. Diagnosis may require special
histological stains, immuno-histochemistry, ultrastruc-
tural and/or cytogenetic analysis [4,6].
Treatment and prognosis
The prognosis has historically been extremely bleak,
with median survivals of less than 1 year without
treatment from the time of diagnosis, and with most dying
within 2 years of diagnosis. Death typically occurs from
respiratory failure, cardiac dysfunction secondary to local
invasion, or bowel obstruction from transdiaphragmatic
spread. There is no consensus on treatment, which
includes supportive and palliative therapy, and single
modality to aggressive multimodality strategies [5].
Radical surgery offers the best hope of long-term
survival. Surgical options include extrapleural pneu-
monectomy (EPP, ‘pleuropneumonectomy’) or decortica-
tion (‘pleurectomy’). EPP involves the en-bloc resection
of the parietal pleura, lung, ipsilateral hemidiaphragm,
and ipsilateral pericardium, typically with prosthetic
reconstruction or reinforcement of the diaphragm and
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pericardium. Decortication, which is associated with
lower peri-operative morbidity, involves stripping of the
pleura, but typically the diaphragmatic and mediastinal
pleura cannot be completely removed. It is employed in
extremely limited disease, or conversely, in advanced dis-
ease as a cytoreductive or palliative procedure, the latter
most commonly being an attempt to prevent recurrent
pleural effusions. Sadly, few patients have operable dis-
ease. Furthermore, local recurrences are common because
microscopic clearance is difficult to achieve. Although
some isolated long-term survivals following surgery have
been reported, they are distinctly uncommon.
Radiotherapy is limited by the typically large target
volumes involved and consequent toxicity to adjacent
organs. Furthermore, the tumour tends to be relatively
radio-resistant, with local tumour progression reported
with substantial doses of up to 70 Gray. The tumour is
also relatively chemo-insensitive, with typical response
rates of less than 20% [4], although more promising
response rates of greater than 40% have recently
been reported with combinations of pemetrexed or
gemcitabine with cisplatin.
Combinations of surgery and radiotherapy and/or
chemotherapy have been undertaken in varying patient
groups. A study of 183 patients has raised the possibility
that multimodality treatment with EPP, followed by
adjuvant chemotherapy and radiotherapy, can improve
median survival to 19 months, with survivals of 38%
at 2 years, and 15% at 5 years [7]. One advantage
of this approach is that higher doses of radiotherapy
can be delivered, as one of the limiting factors in
radiation delivery is the toxic effects on lung parenchyma.
It should, however, be noted that these results were
achieved in a highly selected group of patients.
Other more experimental treatments include
immunotherapy, gene therapy, photodynamic therapy,
and tyrosine kinase and angiogenesis inhibitors.
A number of prognostic factors have been proposed
including the presence of pain, weight loss, anaemia,
leucocytosis, thrombocytosis, and poor performance
status and age. However, there is uniform agreement that
non-epithelial histology and advanced stage disease carry
a poor prognosis [3,7].
Staging
A number of staging systems have been proposed, but
have been under debate for their prognostic validity and
clinical utility. Probably the most widely used system
historically was that proposed by Butchart in 1976; for
comparative purposes, a more recent ‘Brigham’ system,
which is essentially a surgically based system, is also
presented (Table 1).
A TNM-based system proposed by the International
Mesothelioma Interest Group (IMIG) in 1995, has
recently been adopted by the American Joint Committee
on Cancer (AJCC/UICC, 2002), and is presented in
Table 2. Excellent diagrams illustrating the T-staging can
be reviewed elsewhere [8].
It should be noted that most patients have advanced
disease at presentation, 70–80% Stage III disease; and
only 8–18% Stage I.
Role of imaging at diagnosis
The onset of symptoms of MPM is typically insidious
and non-specific, including dyspnoea, chest pain, cough,
weight loss, and general malaise, which contributes to
the late presentation in most cases. Chest radiography
is generally the first radiological investigation, and
allows radiologists the opportunity to be instrumental in
suggesting the diagnosis at outset.
The typical features of MPM are of pleural thickening,
which may be focal or diffuse, uniform or nodular, and
may extend into the interlobar fissures. On occasions,
the pleural thickening may be comparatively minor and,
indeed, may be obscured by what appears to be a simple
pleural effusion. Pleural fluid, which may be large at
the time of presentation, may be loculated in the pleural
cavity or fissures. One suggested clue to the possibility
of MPM is the lack of mediastinal shift in the presence
of extensive pleural disease, attributed to the encasement
of the pleura by the solid rind and fixation of the
mediastinum.
Computed tomography
Computed tomography (CT) of the chest is the next most
appropriate investigation, as it allows better delineation of
the pleural disease, differentiation of pleural thickening
and pleural fluid, and extent of local disease within the
thorax, and is the primary staging modality.
The findings reflect those described on gross pathology
above, but are unfortunately entirely non-specific, and
differentiation of malignant from benign disease is
challenging, let alone differentiation of MPM from other
malignant pleural diseases, such as metastases, which are
in fact more common. Features that suggest a malignant
aetiology include a circumferential distribution or lung
encasement, nodular morphology, pleural thickening of
greater than 1 cm, and involvement of the mediastinal
pleura.
Co-existent stigmata of previous asbestos exposure,
e.g. pleural calcification and interstitial lung disease
(asbestosis), which in principle would be useful clues,
are not frequently seen. A further difficulty in diagnosis
is that asbestos exposure itself is also associated with
the production of benign pleural plaques, which can be
difficult to differentiate from MPM, although the former
characteristically have sharp edges, and is separate from
the extrapleural fat and endothoracic fascia. Diffuse
pleural thickening may also occur in association with
asbestos-related pulmonary fibrosis, i.e. asbestosis.
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Table 1 Comparative staging systems for MPM: Butchart and ‘Brigham’ systems
Stage Butchart system ‘Brigham’ system
I Tumour confined within the ‘capsule’ of the parietal pleura,
i.e. ipsilateral lung, pericardium
Disease completed resected within the capsule of the parietal
pleura without adenopathy; ipsilateral pleura, lung,
pericardium, diaphragm, or chest-wall disease limited to
previous biopsy sites
II Tumour invading chest wall or involving mediastinal
structures, e.g. oesophagus, heart; intrathoracic nodal
involvement
All of stage I with positive resection margins and/or
intrapleural adenopathy
III Tumour penetrating diaphragm to involve peritoneum directly,
extrathoracic nodal involvement
Local extension of disease into chest wall or mediastinum,
heart, or through diaphragm, peritoneum, or with extrapleural
lymph node involvement
IV Distant haematogenous metastases Distant metastatic disease
Table 2 TNM (IMIG) and (AJCC/UICC) staging system for diffuse MPM
Stage Findings
T stage T1a Tumour limited to parietal pleura
T1b Tumour involving parietal pleura, with foci in visceral pleura
T2 Tumour involving pleura with one of the following: involvement of diaphragmatic muscle confluent
visceral pleural tumour (including fissures) or extension of tumour from visceral pleura into underlying
pulmonary parenchyma
T3 Locally advanced, but potentially resectable tumour. Tumour involving all pleural surfaces with at least
one of the following: involvement of endothoracic fascia; exension into mediastinal fat; solitary,
completely respectable focus of tumour extending into soft tissues of chest wall; non-transmural
involvement of pericardium
T4 Locally advanced, but technically unresectable. Tumour involving all pleural surfaces with at least one of
the following: Diffuse extension or multifocal masses of tumour in chest wall, with or without associated
rib destruction; direct transdiaphragmatic extension of tumour to peritoneum; direct extension of tumour to
contralateral pleura; direct extension to one or more mediastinal organs, e.g. direct extension of tumour
into spine; extension through internal surface of pericardium, with or without pericardial effusion, or
involvement of myocardium
N stage NX Not assessable
N0 No regional nodal metastases
N1 Ipsilateral bronchopulmonary or hilar metastases
N2 Ipsilateral mediastinal or subcarinal metastases
N3 Contralateral mediastinal, contralateral internal mammary, or ipsilateral or contralateral supraclavicular
metastases
M stage MX Not assessable
M0 No distant metastases
M1 Distant metastases
Stage grouping TNM equivalent
Ia T1a N0 M0
Ib T1b N0 M0
II T2 N0 M0






As with other pathological processes, abutment (indi-
cated by loss of fat planes between the tumour and
adjacent organs), even with displacement of structures,
does not necessarily indicate invasion; conversely,
involvement cannot be excluded in these circumstances
(Fig. 1). Infiltration into adjacent organs is more definitive
evidence of involvement, and can sometimes be more
clearly appreciated following intravenous (IV) contrast
administration. Again, however, caution should be exer-
cised, as post-contrast enhancement in adjacent tissues
may be seen as a reactive response.
Signs of rib destruction and invasion into the chest-
wall musculature are strong evidence of chest-wall
involvement (Fig. 2). Assessment for pericardial invasion
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can be difficult, although the presence of pericardial
thickening, especially if nodular, or a pericardial effusion
is suggestive of involvement, although again not specific.
Figure 1 CT showing left MPM with extensive
involvement of the diaphragm, including diaphra-
matic crus and slips (long arrows). There is abutment
and displacement of the descending thoracic aorta
(arrow heads) and distal oesophagus (short arrow),
highly suggestive (but not conclusive) of invasion.
Figure 2 CT showing right MPM with character-
istic diffuse pleural thickening, including involvement
of the mediastinal pleura (short arrows) and oblique
fissure (arrow head), with encasement of the lung and
associated rib destruction (long arrow).
In an early study of 41 patients, evaluating the accuracy
of CT in predicting resectability in three major anatomic
regions (diaphragm, chest wall, and mediastinum), Patz
et al. [9] reported high sensitivities of greater than 90%.
Noticeably, specificity was less than 50%. It should
be noted that just under half the CT examinations
in this study were obtained at 8–10 mm sections on
conventional (non-helical) scanners, and without IV
contrast. Interestingly, no nodal disease was identified in
the patients who had surgery (34 patients).
In a subsequent prospective study of 65 patients
evaluating the accuracy of CT in staging, Heelan et al. [10]
reported accuracies for T stage less than 73% (but
mostly in the 50–60% range), and for nodal N1 or
N2 disease less than 50%. In this study, CTs were
acquired with IV contrast media, but from a mixture of
conventional (10 mm collimation), and helical scanners
(7 mm collimation, 1.5 pitch).
Magnetic resonance imaging
Magnetic resonance imaging (MRI) offers better soft-
tissue contrast compared to CT, and also has a direct
multiplanar capability, which is potentially useful when
trying to assess local invasion. The signs of adjacent
organ involvement are similar to CT.
Typical MRI protocols include axial T1 and T2-
weighted spin-echo sequences, together with coronal
and/or sagittal planes of the affected side. Cardiac
gating and respiratory compensation improve image
quality, but prolong examination times. The tumour is
typically of intermediate signal intensity on T1 weighting
(similar to muscle), and of moderately increased signal
on T2 weighting compared to muscle. Some authors
advocate including IV contrast enhanced breath-hold T1-
weighted fat-suppressed 2D FLASH (fast low angle shot)
sequences [11].
There are some suggestions that MRI may be able
to assist in the differentiation of benign from malignant
disease. A study of 45 patients has suggested that
hypointensity on long TR sequences is a sign of benig-
nity [12]. A further study of 34 patients has reported that
focal thickening and enhancement of interlobar fissures
is more suggestive of malignancy than benignity [11].
These authors also found that enhancement of interlobar
fissures, and invasion of the diaphragm, soft tissues of the
mediastinum and chest wall was more indicative of MPM
than metastatic pleural disease.
An early comparative study of CT (using conventional
scanners) and MRI showed no significant differences
in the accuracy of these two modalities with respect
to predicting resectability of the diaphragm, chest wall,
and mediastinum, with sensitivities of greater than 90%
for both CT and MRI. Noticeably, specificities for both
modalities were less than 50% [9].
A subsequent prospective study has confirmed similar
staging accuracies between CT and MRI, with T-stage
accuracies in the range 50–60% for CT and MRI, and
nodal (N1 or N2) stage disease of less than 50% [10].
Noticeably, however, MR was significantly more accurate
than CT in two areas: diaphragmatic invasion (82% vs.
55%, P = 0.01) and invasion of lung parenchyma (69%
vs. 46%, P = 0.05). Comparative studies utilizing more
modern multidetector CT scanners are awaited.
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Positron emission tomography
The increased metabolic activity of MPM, as with
other malignancies, is reflected in increased 18F-FDG
activity, which can be detected by both positron
emission tomography (PET) and dual-headed gamma-
camera coincidence scanners. In one study of 18 surgical
candidates with MPM, PET showed increased activity
in all subjects [13]. It identified extrathoracic disease
in two patients. It was also more accurate than
CT in identifying mediastinal nodal disease, correctly
identifying involvement in four out of four patients, while
CT only identified nodal enlargement in two of these
patients. Furthermore, CT demonstrated enlarged, but
benign, nodes in two other cases. PET, however, can
generate false-positive (e.g. inflammatory lesions) and
false-negative results (e.g. small lesions). A study of
28 patients has suggested that standardized uptake value
(SUV) levels may have some prognostic significance.
PET may have a role in assisting in differentiating
MPM from other benign processes. A small study of
18 patients has a suggested sensitivity of 92%, specificity
of 75% and accuracy of 89% for detecting MPM [14].
However, it is unlikely to be able to differentiate between
the malignancies, e.g. metastatic pleural disease.
Percutaneous image-guided biopsy
Cytologic examination and fine-needle biopsies are
extremely unreliable in the diagnosis of MPM because of
the difficulties in pathological diagnosis discussed above.
As a result, some surgeons advocate open or thoroscopic
biopsy. Such invasiveness is perhaps unnecessary, since
the reported sensitivities and specificities of CT-guided
biopsies, utilizing 14 or 18-gauge needles, is 86
and 100%, respectively, albeit in a small series of
only 21 cases of MPM. In this study, biopsies were
reportedly achievable from pleural thicknesses of less
than 5 mm [15]. Imaging guidance can also be obtained
with ultrasound. The risks of percutaneous tract seeding
have been suggested at 22%, but are probably overstated.
Nevertheless, prophylactic radiotherapy to the site of
biopsy is generally offered.
Imaging in follow-up
Following an EPP, the pneumonectomy space fills with
fluid more rapidly than following a standard pneu-
monectomy (several days, rather than weeks, following
surgery). The mediastinum usually remains midline,
typically becoming fixed in position within 7–10 days;
contralateral shift may occur if fluid accumulation is
rapid [16]. An early post-operative CT typically shows a
thin soft-tissue rind surrounding the hemithorax. Recur-
rent disease on thoracic CT typically appears as pleural
thickening or a mass, and mediastinal or hilar adenopathy.
Following pneumonectomy, recurrences may be local, but
are more commonly distant [3,4].
There is debate about the appropriate interval and
modality for follow-up. Some argue that routine radio-
graphs are adequate for follow-up, with CT reserved for
new symptoms or radiographic findings (e.g. new air-
fluid level, mediastinal shift, or pulmonary nodules in the
contralateral lung), because it is argued, treatment options
for recurrent disease are limited. Others argue that the
poorer sensitivity of radiographs in relation to CT do not
allow adequate evaluation of disease status and therapy,
and advocate CT every 3 months [5].
There is probably no role for MRI in follow-up. The
role of PET in post-treatment follow-up is undefined;
one potential advantage is its ability to evaluate for local
recurrence and metastatic disease in one study.
Challenges in imaging
The limitations of CT and MRI in pre-operative staging
have been illustrated in a number of clinical series. In one
study of 131 patients, considered to be operable following
CT, 24% were found to be technically unresectable (i.e.
T4 disease), and 35% had mediastinal nodal involve-
ment [3]. In another study of 32 patients considered
operable following both CT and MRI, 16 patients were
under staged (nine had N2, and seven had T4 disease);
the authors concluded ‘pre-operative staging based on
CT/MR looks rather inaccurate’ [17].
There are several contributing factors. As is borne out
in previous sections, the evaluation of mediastinal and
hilar nodal status by both CT and MRI is challenging.
This is in part because nodal size, as in other tumours, is
not a reliable determinant of disease status: small nodes
may contain metastatic disease, and large nodes may
simply be reactive. In addition, in MPM the primary
pleural tumour generally spreads in a confluent, sheet-
like manner, and in the hilar and mediastinal regions can
become inseparable from adjacent nodes; a hilar mass
may represent adenopathy or the pleural tumour itself.
Tumour seedlings, either in the pleura or peritoneum,
are impossible to detect by any current imaging modality.
The differentiation of T1a (limited parietal disease) and
T1b (parietal and visceral disease) also currently cannot
be made radiologically.
These limitations have led some clinicians to advo-
cate that pre-operative evaluation should include tho-
racoscopy, bronchoscopy with transbronchial biopsy,
mediastinoscopy, and/or laparoscopy [7,17].
Summary and future perspectives
Imaging can be invaluable in first suggesting the
diagnosis of MPM. However, unfortunately, there are
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no pathognomonic plain film or cross-sectional imaging
findings, and it is generally not possible to distinguish
MPM from metastatic pleural disease nor, at times, from
benign pleural disease. Equally, pathological diagnosis
can also be challenging.
CT is the mainstay of staging, but it probably
underestimates early chest wall and diaphragmatic
invasion. The multiplanar capability of MRI is superior
in these areas, and should probably be offered to
patients being considered for surgery. However, both
have limitations in local staging. The capabilities of thin-
section, multidetector CT together with the possibilities
for high-quality multiplanar reformation have yet to be
explored.
The scope and extent of initial staging work-up and
follow-up, especially with respect to distant disease, is
undefined and deserves further evaluation, particularly
given the increasing recognition of the prevalence of
distant disease. Unreliable staging is not only detrimental
to surgical candidates, but it inevitably confounds the
accuracy of treatment stratification and evaluations.
Preliminary studies suggest that FDG-PET may be
useful in assessing both local and distant disease at
staging, and potentially also in follow-up. It may also be
useful in distinguishing benign from malignant disease,
and may have some prognostic value.
The utility of PET–CT scanners has yet to be
determined; it holds the promise of combining the high
morphological detail provided by CT and the metabolic
information derived from FDG.
The above challenges in imaging are matched by
controversies in therapy. The main handicap has been
the lack of clinical trials, due largely to the comparative
rarity of the disease and the rapidity of its progression.
Given the expected continuing rise in incidence of MPM
in the coming decades, it would seem vital that all parties
combine forces in a collaborative multidisciplinary
and multicentre effort to determine efficacious staging,
treatment and follow-up protocols.
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